A phase I study of combined radiation therapy with 5-fluorouracil and low dose folinic acid in patients with locally advanced pancreatic or biliary carcinoma

被引:10
作者
Hsue, V
Wong, CS
Moore, M
Erlichman, C
Cummings, BJ
MacLeod, M
机构
[1] PRINCESS MARGARET HOSP,DEPT RADIAT ONCOL,TORONTO,ON M4X 1K9,CANADA
[2] PRINCESS MARGARET HOSP,DEPT MED,TORONTO,ON M4X 1K9,CANADA
[3] PRINCESS MARGARET HOSP,DEPT NURSING,TORONTO,ON M4X 1K9,CANADA
[4] UNIV TORONTO,DEPT RADIAT ONCOL,TORONTO,ON,CANADA
[5] UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1996年 / 34卷 / 02期
关键词
pancreatic carcinoma; radiotherapy; 5-fluorouracil; folinic acid;
D O I
10.1016/0360-3016(95)02032-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the toxicities of a Phase I study of radiation therapy with concurrent 5-fluorouracil (5FU) and low dose folinic acid in patients with locally advanced pancreatic or biliary carcinoma. Methods and Materials: Twenty-seven patients with locally advanced carcinoma of the pancreas (n = 19), bile duct (n = 7), and gall bladder (n = 1) were entered into a Phase I study of combined radiation therapy, 5FU, and folinic acid. Radiation was given as a split course of 40 Gy in 20 daily fractions with a gap of 2 weeks after 20 Gy. 5-Fluorouracil, 300 to 375 mg/m(2)/day and folinic acid, 20 mg/m(2)/day were given as an i.v. bolus daily for 5 days beginning on day 1 and again on day 29. Results: Eight patients developed Grade 3 or 4 toxicities (National Cancer Institute common toxicity criteria) including nausea and vomiting (n = 4), oral mucositis (n = 4), myelosuppression (n = 2), infection (n = 2), and diarrhea (n = 1). Four patients did not complete the planned protocol due to treatment toxicities. There were two treatment deaths secondary to septic neutropenia. Treatment toxicity appeared to be related to age (> 70), performance status (ECOG = 2), and 5FU dose (> 350 mg/m(2)/day). Conclusion: This protocol is poorly tolerated by elderly patients or those with poor performance status, and 350 mg/m(2)/day is our recommended dose for 5FU as given in this protocol.
引用
收藏
页码:445 / 450
页数:6
相关论文
共 50 条
[21]   5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma [J].
Seitz, JF ;
Perrier, H ;
Giovannini, M ;
Capodano, G ;
Bernardini, D ;
Bardou, VJ .
JOURNAL OF CHEMOTHERAPY, 1998, 10 (03) :258-265
[22]   Paclitaxel, 5-fluorouracil and hydroxyurea concurrent with radiation in locally advanced nasopharyngeal carcinoma [J].
Wong, A. S. C. ;
Soo, R. A. ;
Lu, J. J. ;
Loh, K. S. ;
Tan, K. S. ;
Hsieh, W. S. ;
Shakespeare, T. P. ;
Chua, E. T. ;
Lim, H. L. ;
Goh, B. C. .
ANNALS OF ONCOLOGY, 2006, 17 (07) :1152-1157
[23]   Cisplatin, 5-fluorouracil, and high-dose folinic acid in patients with advanced unresectable head and neck cancer [J].
Alba, E ;
SanchezChaparro, MA ;
Alonso, L ;
Ribelles, N ;
Delgado, JR ;
Rueda, A ;
Tenllado, PP ;
Solano, J ;
Urquiza, R .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (02) :140-143
[24]   Analysis of the clinical benefit of 5-fluorouracil and radiation treatment in locally advanced pancreatic cancer [J].
Fisher, BJ ;
Perera, FE ;
Kocha, W ;
Tomiak, A ;
Taylor, M ;
Vincent, M ;
Bauman, GS .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (02) :291-295
[25]   A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer [J].
Gomez-Martin, C. ;
Salazar, R. ;
Montagut, C. ;
Gil-Martin, M. ;
Nunez, J. A. ;
Puig, M. ;
Lin, X. ;
Khosravan, R. ;
Tursi, J. M. ;
Lechuga, M. J. ;
Bellmunt, J. .
INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) :390-398
[26]   A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer [J].
C. Gómez-Martín ;
R. Salazar ;
C. Montagut ;
M. Gil-Martín ;
J. A. Núñez ;
M. Puig ;
X. Lin ;
R. Khosravan ;
J. M. Tursi ;
M. J. Lechuga ;
J. Bellmunt .
Investigational New Drugs, 2013, 31 :390-398
[27]   Oxaliplatin, folinic acid and 5-fluorouracil (OFF) in patients with recurrent advanced head and neck cancer: A phase II feasibility study [J].
Raguse, Jan Dirk ;
Gath, Hans Joachim ;
Oettle, Helmut ;
Bier, Juergen .
ORAL ONCOLOGY, 2006, 42 (06) :614-618
[28]   Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck [J].
Tsukuda M. ;
Mikami Y. ;
Tanigaki Y. ;
Katori H. ;
Horiuchi C. ;
Ikeda Y. ;
Taguchi T. ;
Ono M. ;
Yoshida T. ;
Sakuma Y. ;
Aikoh K. .
International Journal of Clinical Oncology, 2004, 9 (3) :161-166
[29]   A phase II study of 5-fluorouracil and high dose folinic acid in cisplatin refractory metastatic bladder cancer [J].
Huan, SD ;
Aitken, SE ;
Stewart, DJ .
ANNALS OF ONCOLOGY, 1995, 6 (08) :836-837
[30]   A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial [J].
Ducreux, M ;
van Cutsem, E ;
van Laethern, JL ;
Gress, TM ;
Jeziorski, K ;
Rougier, P ;
Wagener, T ;
Anak, O ;
Baron, B ;
Nordlinger, B .
EUROPEAN JOURNAL OF CANCER, 2005, 41 (03) :398-403